NCT05836779View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

November 29, 2023

Study Completion Date

January 5, 2024

Conditions
Cellulite
Interventions
DRUG

CBL-514 injection

CBL-514 will be administered at the raised area of cellulite.

Trial Locations (5)

10022

Investigational Site 2, New York

33146

Investigational Site 4, Coral Gables

91436

Investigational Site 1, Encino

92024

Investigational Site 6, Encinitas

92121

Investigational Site 3, San Diego

Sponsors
All Listed Sponsors
lead

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT05836779 - A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) | Biotech Hunter | Biotech Hunter